Movetis NV

TURNHOUT, Belgium - Movetis, the GI specialty pharmaceutical company based in Belgium announces today that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) on the European Marketing Authorisation Application (MAA) for its lead product, prucalopride for the treatment of chronic constipation (CC).

CHICAGO - Data from 7 prucalopride trials are being presented at the Digestive Disease Week (DDW) in Chicago.